EXELIXIS INC's ticker is EXEL and the CUSIP is 30161Q104. A total of 342 filers reported holding EXELIXIS INC in Q2 2021. The put-call ratio across all filers is 1.12 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $601,885 | +5.8% | 37,524 | +3.4% | 0.08% | -41.7% |
| Q3 2022 | $569,000 | -20.8% | 36,299 | +5.3% | 0.14% | -4.8% |
| Q2 2022 | $718,000 | -16.6% | 34,479 | -9.2% | 0.15% | -4.6% |
| Q1 2022 | $861,000 | +21.4% | 37,979 | -2.0% | 0.15% | +29.7% |
| Q4 2021 | $709,000 | -7.6% | 38,765 | +6.9% | 0.12% | -13.2% |
| Q3 2021 | $767,000 | +27.0% | 36,265 | +9.4% | 0.14% | +23.6% |
| Q2 2021 | $604,000 | -20.1% | 33,146 | -1.0% | 0.11% | -36.4% |
| Q1 2021 | $756,000 | +28.4% | 33,473 | +14.0% | 0.17% | +16.9% |
| Q4 2020 | $589,000 | +1269.8% | 29,372 | +1554.8% | 0.15% | +957.1% |
| Q3 2020 | $43,000 | -34.8% | 1,775 | -36.0% | 0.01% | -44.0% |
| Q2 2020 | $66,000 | +37.5% | 2,775 | 0.0% | 0.02% | +13.6% |
| Q1 2020 | $48,000 | -2.0% | 2,775 | 0.0% | 0.02% | +22.2% |
| Q4 2019 | $49,000 | -19.7% | 2,775 | -20.1% | 0.02% | -33.3% |
| Q3 2019 | $61,000 | -48.7% | 3,475 | -38.2% | 0.03% | -47.1% |
| Q2 2019 | $119,000 | – | 5,625 | – | 0.05% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Meditor Group Ltd | 15,001,073 | $320,572,000 | 64.48% |
| Sargent Investment Group, LLC | 432,125 | $9,235,000 | 4.22% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 443,534 | $9,483,000 | 3.52% |
| Bellevue Group AG | 3,878,800 | $82,890,000 | 1.42% |
| CAPITAL MANAGEMENT CORP /VA | 237,855 | $5,083,000 | 1.40% |
| Orbimed Advisors | 3,912,900 | $83,619,000 | 1.30% |
| Portolan Capital Management | 540,590 | $11,552,000 | 1.24% |
| TEALWOOD ASSET MANAGEMENT INC | 139,347 | $2,978,000 | 1.21% |
| Signition LP | 84,120 | $1,798,000,000 | 1.18% |
| Penn Capital Management Company, LLC | 529,630 | $11,318,000 | 1.12% |